Kezdőlap・Részvénylista・Myriad Genetics Inc

Myriad Genetics Inc

Lezárt

SzektorEgészségügy

3.06 -1.92

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3.03

Maximum

3.25

Fő mutatók
By Trading Economics
Bevétel	-9.1M -43M
Értékesítés	-9.7M 191M
Egy részvényre jutó nyereség	-0.33
Profit margin	-22.653
Munkavállalók	2,700
EBITDA	-21M -39M

Ajánlások
By TipRanks
Ajánlások	Semleges
12 hónapos előrejelzés	+81.07% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 2.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-230M 285M
Előző nyitás	4.98
Előző zárás	3.06

Myriad Genetics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 5. 21:21 UTC

Myriad Genetics Inc shares are higher in after-market hours, reflecting broader market gains amid positive technology stock performance and favorable economic data.

2026. aug. 4. 20:04 UTC

Myriad Genetics shares are higher today, supported by overall market gains and positive sentiment amid declining crude oil prices and comments on potential peace talks with Iran.

2026. aug. 3. 20:03 UTC

News

Myriad Genetics gains amid broader market strength, tightening revenue guidance to $770 million to $790 million while facing reimbursement challenges. Shares remain higher since Friday.

2026. júl. 31. 23:11 UTC

Myriad Genetics Inc shares are higher in after-market hours, recovering from earlier lows. The stock remains below its 20-day moving average.

2026. júl. 30. 22:51 UTC

News

Myriad Genetics shares fell in after-market trading following disappointing Q2 results, with revenue of $190.7 million missing expectations and a revised revenue outlook.

2026. júl. 29. 18:07 UTC

Myriad Genetics Inc. shares are lower today, continuing a four-session decline amid broader market concerns over rising crude oil prices and inflation worries.

2026. júl. 28. 18:06 UTC

News

Myriad Genetics faces negative sentiment after being labeled unprofitable. Shares are lower today, continuing a trend of declines over the past three sessions.

2026. júl. 27. 18:16 UTC

Myriad Genetics shares are lower amid a broader market trend and significant declines in crude oil prices, despite earlier session volatility.

2026. júl. 24. 19:36 UTC

Event

News

Myriad Genetics shares are lower amid scrutiny over financial performance and stagnant revenue growth, reflecting ongoing challenges in the broader market.

2026. júl. 22. 20:06 UTC

Myriad Genetics Inc shares are lower today, continuing a decline from Tuesday's close amid mixed sentiment ahead of the Federal Reserve meeting.

2026. júl. 20. 18:22 UTC

Myriad Genetics Inc. shares are lower today, continuing a recent decline amid rising U.S. Treasury yields and inflation concerns tied to increasing oil prices.

Társak összehasonlítása

Árváltozás

Myriad Genetics Inc Előrejelzés

Célár

By TipRanks

81.07% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 5.74 USD 81.07%

Magas 10 USD

Alacsony 3 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Myriad Genetics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

6 ratings

Vétel

Tartás

Eladás

6 Wall Street elemző célárain alapulva a(z)Myriad Genetics Inc termékhez az elmúlt 3 hónapban.

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.